Rebiotix
If you are interested in the donor program, click on the donor program below.. Donor Program
C diff Clinical Study at MNGI Digestive Health, Plymouth, MN
The study drug, RBX2660, is approved by the US Food and Drug Administration (FDA), and marketed in the United States as REBYOTA™ (fecal microbiota, live – jslm) 1 for rectal administration only. Study doctors want to find out if RBX2660 is also effective in preventing CDI recurrence when given by colonoscopy.
C diff Clinical Study at Mayo Clinic Rochester, MN
The study drug, RBX2660, is approved by the US Food and Drug Administration (FDA), and marketed in the United States as REBYOTA™ (fecal microbiota, live – jslm) 1 for rectal administration only. Study doctors want to find out if RBX2660 is also effective in preventing CDI recurrence when given by colonoscopy.
THE MICROBIOTA-BASED DRUG RBX2660 IS EFFICACIOUS AND SAFE IN PATIENTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTIONS: RESULTS FROM 2 CONTROLLED CLINICAL TRIALS Robert’Orenstein’DO1,Erik’Dubberke MD’MSPH2,SahilKhanna’MBBS4,Gail’Hecht’MD4,Herbert’Dupont …